No Absolute Contraindications to Pneumococcal Vaccination with Methotrexate
Pneumococcal vaccination is NOT contraindicated in patients receiving methotrexate—it should be administered, though methotrexate may reduce vaccine immunogenicity. The only absolute contraindications to pneumococcal vaccines are severe allergic reactions to vaccine components or diphtheria toxoid 1, 2.
Key Clinical Guidance
Methotrexate Does Not Prohibit Vaccination
The FDA label for methotrexate states that "immunization may be ineffective when given during methotrexate therapy" but does NOT list pneumococcal vaccination as contraindicated 2. The contraindication applies only to patients with "overt or laboratory evidence of immunodeficiency syndromes" in the context of psoriasis or rheumatoid arthritis 2.
Continue Methotrexate During Pneumococcal Vaccination
The 2022 ACR guideline explicitly recommends continuing methotrexate during non-influenza vaccinations, including pneumococcal vaccines 3. This differs from influenza vaccination, where holding methotrexate for 2 weeks post-vaccination is conditionally recommended if disease activity allows 3.
Understanding the Immunogenicity Trade-off
Methotrexate Reduces But Does Not Eliminate Vaccine Response
Multiple studies demonstrate that methotrexate blunts antibody responses to pneumococcal vaccination:
- Methotrexate reduces humoral response with odds ratios of 0.33-0.58 for specific serotypes compared to controls 4
- Patients on methotrexate alone showed the lowest immune responses compared to those on TNF blockers 5
- Despite reduced response, 80% of RA patients on methotrexate still achieved protective antibody levels 6
Long-term Protection Remains Effective
Importantly, a single pneumovax administration provides up to 10 years of protection in RA patients on methotrexate 7. Vaccinated patients maintained significantly higher antibody levels than unvaccinated patients, and unvaccinated patients had a 9.7-fold increased risk of pneumonia 7.
Optimal Vaccination Strategy
Timing Considerations
Ideally, administer pneumococcal vaccine BEFORE initiating methotrexate when possible 6, 8. A 2025 randomized trial showed that delaying methotrexate for 1 month after PCV13 vaccination resulted in 1.46-1.65 times higher responder rates without compromising disease control 8.
However, if the patient is already on methotrexate:
- Vaccinate anyway—do not delay vaccination 3
- Some protection is better than no protection
- The vaccine remains effective despite reduced immunogenicity
Current Vaccine Options
Per 2024 ACIP recommendations, adults aged ≥50 years should receive 1:
- PCV21, PCV20, or PCV15 (if PCV15 is used, follow with PPSV23 ≥1 year later)
- For patients 19-64 years with chronic conditions (including those on immunosuppressive therapy), the same recommendations apply
Critical Pitfalls to Avoid
- Do not withhold pneumococcal vaccination because a patient is on methotrexate—this is NOT a contraindication
- Do not hold methotrexate around the time of pneumococcal vaccination (unlike influenza vaccine) 3
- Do not confuse reduced immunogenicity with contraindication—reduced response does not mean no response
- Avoid live vaccines (not applicable here, as pneumococcal vaccines are inactivated) 2
Special Populations
For patients on combination therapy (methotrexate + biologics), the methotrexate component drives the reduced response more than TNF blockers 4, 5. Rituximab causes more significant immunosuppression than methotrexate and requires different timing strategies 3.